Background And Objective: Post-stroke constipation (PSC) is a common complication of strokes that seriously affects the recovery and quality of life of patients, and effective treatments are needed. Acupuncture is a viable treatment option, but current evidence is insufficient to support its efficacy and safety. This study aims to evaluate the efficacy and safety of acupuncture in the treatment of PSC.
Methods: A systematic search of eight databases was conducted to identify PSC-related randomized clinical trials from the inception of each database through May 2023. Methodological quality assessment was conducted by RoB 2.0, meta-analysis was conducted by RevMan 5.3 and Stata 15.1, and evidence quality was evaluated by GRADE. Moreover, reporting quality of acupuncture interventions was assessed using the Standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA).
Results: Thirty RCTs involving 2,220 patients were identified. We found that acupuncture was superior to conventional treatment (CT) in improving total responder rate [risk ratio (): 1.16, 95% confidence interval (CI): 1.09 to 1.25, < 0.0001], decreasing constipation symptom scores [standardized mean difference (): -0.65, 95% CI: -0.83 to -0.46, < 0.00001], increasing serum P substance (SP) levels (: 1.92, 95% CI: 0.47 to 3.36, = 0.009), reducing the time to first bowel movement (BM) (: -1.19, 95% CI: -2.13 to -0.25, = 0.01), and lowing serum vasoactive intestinal peptide (VIP) levels (: -2.11, 95% CI: -3.83 to -0.38, = 0.02). Furthermore, acupuncture plus CT was superior regarding total responder rate (: 1.26, 95% CI: 1.17 to 1.35, < 0.00001), serum SP levels (: 2.00, 95% CI: 1.65-2.35, < 0.00001), time to first BM (: -2.08, 95% CI: -2.44 to -1.71, < 0.00001), and serum VIP levels (: -1.71, 95% CI: -2.24 to -1.18, < 0.00001). However, regarding Bristol Stool Scale (BSS) score, acupuncture plus CT was superior to CT (: -2.48, 95% CI: -3.22 to -1.73, < 0.00001), while there was no statistically significant difference between acupuncture and CT (: 0.28, 95% CI: -0.02 to 0.58, = 0.07). Acupuncture causes fewer AEs than CT (: 0.13, 95% CI: 0.06 to 0.26, < 0.00001), though there was no statistically significant difference between acupuncture plus CT vs. CT (: 1.30, 95% CI: 0.60 to 2.84, = 0.51).
Conclusion: Acupuncture may be an effective and safe therapy for PSC. However, given the inferior quality of clinical data, additional well-designed RCTs are required to confirm these findings.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562632 | PMC |
http://dx.doi.org/10.3389/fnins.2023.1275452 | DOI Listing |
J Cancer Res Ther
December 2024
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.
Background: Patients with transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have limited treatment options and poor outcomes.
Methods: This phase III study (NCT04236141) evaluated the efficacy and safety of polatuzumab vedotin plus bendamustine and rituximab (Pola+BR) versus BR in Chinese patients with transplant-ineligible R/R DLBCL to support regulatory submission in China. Patients were randomized 2:1 to receive Pola+BR or placebo+BR.
J Cancer Res Ther
December 2024
Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, P. R. China.
Background: Endoscopic submucosal dissection (ESD) is a standardized procedure for intramucosal and slightly invasive submucosal colorectal cancers (CRC). However, the role of ESD for T1b (depth of submucosal invasion: ≥1,000 μm) CRC remains unclear. This study aimed to investigate the long-term efficacy and safety of ESD for T1b CRC.
View Article and Find Full Text PDFCNS Drugs
January 2025
School of Medicine and Dentistry, Gold Coast Campus, Griffith University, Southport, QLD, 4222, Australia.
Background: Epstein-Barr virus (EBV) is implicated as a necessary factor in the development of multiple sclerosis (MS) and may also be a driver of disease activity. Although it is not clear whether ongoing viral replication is the driver for MS pathology, MS researchers have considered the prospect of using drugs with potential efficacy against EBV in the treatment of MS. We have undertaken scientific and lived experience expert panel reviews to shortlist existing licensed therapies that could be used in later-stage clinical trials in MS.
View Article and Find Full Text PDFNeurosurg Rev
January 2025
Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Stereotactic radiosurgery (SRS) and radiotherapy (SRT) have gained prominence as both adjuvant and primary treatment options for patients with skull base tumors that are either inoperable or present as residual or recurrent lesions post-surgery. The object of the current study is to evaluate the safety and efficacy of robotic-assisted SRS and SRT across various skull base pathologies. The study was conducted under PRISMA guidelines and involved a comprehensive evaluation of databases, including PubMed, Scopus, Embase, Web-of-Science, and the Cochrane Library.
View Article and Find Full Text PDFNeurosurg Rev
January 2025
Department of Neurointervention, The First Affiliated Hospital of Zhengzhou University, 450052, Zhengzhou, Henan, China.
To evaluate the safety and efficacy of staged coiling followed by flow diverter (FD) in the treatment of ruptured intracranial aneurysms(RIAs). A retrospective analysis was conducted on 20 patients with RIAs treated with staged coiling followed by FD at a single center, between April 2015 and September 2024. Patient demographics, aneurysm characteristics, clinical and imaging outcomes were reviewed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!